



文章

找到约 41 条结果 (用时0.10秒)

时间不限

2017以来

2016以来

2013以来

自定义范围...

按相关性排序

按日期排序

不限语言

中文网页

简体中文网页

☐ 包括专利☐ 包含引用☒ 创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

[\[HTML\] The CpG island methylator phenotype \(CIMP\) in colorectal cancer](#)[\[HTML\] nih.gov](#)

[EN Mojarad](#), [PJK Kuppen](#), [HA Aghdaei](#), ... - ... and hepatology from ..., 2013 - [ncbi.nlm.nih.gov](#)
... tumor suppressor genes (TSGs) and oncogenes such as APC, TP53, KRAS, CTNNB1, and PIK3CA, and LOH ... tumors are the high rate of mutations (KRAS or BRAF), wild type p53, proximal colon ... is believed to be driven by genetic alterations, such as mutations in TP53, but may ...

☆ 99 被引用次数: 47 相关文章 所有 12 个版本

[Molecular predictors of response to chemotherapy in colorectal cancer](#)

[R Dienstmann](#), [E Vilar](#), [J Tabernero](#) - The Cancer Journal, 2011 - [journals.lww.com](#)

Colorectal cancer (CRC) is one of the leading causes of cancer mortality worldwide. In the last deca.

☆ 99 被引用次数: 40 相关文章 所有 4 个版本

[Implementing prognostic and predictive biomarkers in CRC clinical trials](#)

[S Van Schaeybroeck](#), [WL Allen](#), ... - Nature reviews Clinical ..., 2011 - [nature.com](#)

... phenotype has been associated with MSI, BRAF V600E mutations, wild-type TP53, right-sided ... of critical cancer mutations (such as mutations in KRAS, BRAF and PIK3CA genes) in ... Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from ...

☆ 99 被引用次数: 92 相关文章 所有 9 个版本

[\[HTML\] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer](#)[\[HTML\] nejm.org](#)

[T André](#), [C Boni](#), [L Mounedji-Boudiaf](#), ... - ... England Journal of ..., 2004 - [Mass Medical Soc](#)

... after curative surgery occur within the first three years, we consider our results in this ... the treatment, indicating that FL plus oxaliplatin benefited both stage II and stage III colorectal cancer. From a clinical standpoint, stage II colon cancer occurs in a heterogeneous, node-negative ...

☆ 99 被引用次数: 2996 相关文章 所有 20 个版本

[The role of personalized medicine in metastatic colorectal cancer: an evolving](#)[\[HTML\] nih.gov](#)

13

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 37088

Manuscript Type: ORIGINAL ARTICLE

*Retrospective Study**PIK3CA* and *TP53* mutations predict overall survival of stage II/III

colorectal cancer patients

Li AJ *et al.* *PIK3CA/TP53* co-mutation in colorectal cancer

A-Jian Li, Hua-Guang Li, Er-Jiang Tang, Wei Wu, Ying Chen, Hui-Hong

Jiang, Mou-Bin Lin, Lu Yin

符合内容总览

1	互联网 75 个字 于 2016 年 04 月 13 日 缓慢进行 www.ijcem.com	2%
2	互联网 36 个字 于 2014 年 05 月 24 日 缓慢进行 archsix.com	1%
3	Crossref 28 个字 Nina Lapke, Yen-Jung Lu, Chun-Ta Liao, Li-Yu Lee, Chien-Yui Lin, Hung-Ming Wang, Shu-Han	1%
4	互联网 17 个字 于 2014 年 05 月 09 日 缓慢进行 molpath.ucsd.edu	<1%
5	Crossref 17 个字 Changhua Zhuo, Qingguo Li, Yuchen Wu, Yiwei Li <i>et al.</i> "TINP-1 hypomethylation in normal colo	<1%
6	互联网 16 个字 于 2016 年 02 月 20 日 缓慢进行 www.mdpi.com	<1%
7	互联网 15 个字 于 2014 年 05 月 09 日 缓慢进行 mials.bjc.a014178oxfordjournals.org	<1%
8	Crossref 15 个字 Wade S. Samowitz. "Prognostic significance of p53 mutations in colon cancer at the population	<1%
9	互联网 15 个字 于 2017 年 08 月 31 日 缓慢进行 uu.diva-portal.org	<1%
10	Crossref 14 个字 C. Mao. "PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoc	<1%



PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal c



文章

找到约 1,320 条结果 (用时0.10秒)

时间不限

2017以来

2016以来

2013以来

自定义范围...

按相关性排序

按日期排序

不限语言

中文网页

简体中文网页

☐ 包括专利

☐ 包含引用

☒ 创建快讯



小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

Prognostic Role of *KRAS* and *BRAF* in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC ...

AD Roth, S Tejpar, M Delorenzi, P Yan... - Journal of clinical ..., 2009 - [ascopubs.org](#)

... 14,15 Many other studies have investigated the prognostic value of *KRAS* and *BRAF* tumor mutations on retrospectively collected cohorts ... results; some reporting no prognostic value, others finding prognostic value either alone or concomitantly with mutated *TP53* or *PIK3CA* ...

☆ 99 被引用次数: 803 相关文章 所有 10 个版本

[\[HTML\]](#) [ascopubs.org](#)

Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations

D Mouradov, E Domingo, P Gibbs... - The American journal of ..., 2013 - [nature.com](#)

... In joint analyses with mutation data from *KRAS*, *NRAS*, *BRAF*, *PIK3CA*, *FBXW7*, and *TP53*, MSI and the ... *p53* is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and ...

☆ 99 被引用次数: 78 相关文章 所有 16 个版本

[\[HTML\]](#) [nature.com](#)

Poor survival associated with the *BRAF* V600E mutation in microsatellite-stable colon cancers

WS Samowitz, C Sweeney, J Herrick, H Albertsen... - Cancer research, 2005 - AACR

... defined as colorectal cancer in a first-degree relative), mutations in *Ki-ras* and *p53*, and CIMP ... CIMP high was particularly strong (OR, 39.39; 95% CI, 11.90-130.41), as 91.4% of *BRAF* mutated tumors were ... *BRAF* and *Ki-ras* mutations were, with one exception, mutually exclusive ...

☆ 99 被引用次数: 604 相关文章 所有 7 个版本

[\[HTML\]](#) [aacrjournals.org](#)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

J Souglakos, J Philips, R Wang, S Marwah... - ... journal of cancer, 2009 - [nature.com](#)

[\[HTML\]](#) [nature.com](#)

[全部](#)[图片](#)[新闻](#)[购物](#)[视频](#)[更多](#)[设置](#)[工具](#)

找到约 62,200 条结果 (用时 0.58 秒)

Google 学术 : PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients

... and BRAF in stage II and III resected colon cancer: ... - Roth - 被引用次数 : 802

... stage II/III colorectal cancer is independently predicted ... - Mouradov - 被引用次数 : 78

... V600E mutation in microsatellite-stable colon cancers - Samowitz - 被引用次数 : 605

Survival in stage II/III colorectal cancer is independently predicted by ...

<https://www.nature.com> > ... > original contribution - 翻译此页

作者 : CC Holmes - 2013 - 被引用次数 : 78 - 相关文章

2013年9月17日 - We evaluated the prognostic value (disease-free survival, DFS) of CIN, MSI, mutations in KRAS, NRAS, BRAF, PIK3CA, FBXW7, and TP53, and chromosome 18q loss-of-heterozygosity (LOH) in 822 patients from the VICTOR trial of stage II/III CRC. We followed up promising associations in an Australian ...

A multigene mutation classification of 468 colorectal cancers reveals a ...

www.nature.com > nature communications > articles - 翻译此页

作者 : MJ Schell - 2016 - 被引用次数 : 19 - 相关文章

2016年6月15日 - Here we report targeted exome-sequencing of 1,321 cancer-related genes on 468 tumour specimens, which identified a subset of 17 genes that best classify CRC, with APC playing a central role in predicting overall survival. APC may assume 0, 1 or 2 truncating mutations, each with a striking differential ...

PIK3CA mutations predict recurrence in localized microsatellite stable ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380963/> - 翻译此页

作者 : G Manceau - 2015 - 被引用次数 : 13 - 相关文章

2015年2月2日 - 67%, Log-rank P = 0.04). Our study showed that PIK3CA mutations are associated with a good prognosis in patients with MSS stage I-III CC. ... This gene is one of the most frequently mutated genes (16%) in colorectal cancer (CRC), after notably TP53 (51%), APC (37%), and KRAS (36%) 2. In the signal ...

TP53 mutations predict disease control in metastatic colorectal cancer ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676556/> - 翻译此页

作者 : A Oden-Gangloff - 2009 - 被引用次数 : 73 - 相关文章

2009年4月14日 - KRAS and TP53 status were assessed in tumours from 64 metastatic colorectal